Elevation Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Elevation Oncology's estimated annual revenue is currently $5.7M per year.
- Elevation Oncology's estimated revenue per employee is $150,921
- Elevation Oncology's current valuation is $145.4M. (January 2022)
Employee Data
- Elevation Oncology has 38 Employees.
- Elevation Oncology grew their employee count by -12% last year.
Elevation Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and Advisor | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Clinical Operations | Reveal Email/Phone |
4 | VP, Legal Affairs | Reveal Email/Phone |
5 | VP, Program Management & Strategic Alliance | Reveal Email/Phone |
6 | VP Corporate Development | Reveal Email/Phone |
7 | VP, Regulatory Affairs | Reveal Email/Phone |
8 | VP, Legal Affairs | Reveal Email/Phone |
9 | Director, Financial Planning & Analysis | Reveal Email/Phone |
10 | Director Business Operations TechOps | Reveal Email/Phone |
Elevation Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Elevation Oncology?
Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with our peers we work towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey. Our lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Learn more about CRESTONE at www.NRG1fusion.com. Elevation Oncology is backed by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$5.7M
Revenue (est)
-12%
Employee Growth %
$145.4M
Valuation
N/A
Accelerator
Elevation Oncology News
Hedge funds and other institutional investors own 78.42% of the company's stock. Get Elevation Oncology alerts: A number of research analysts...
Elevation Oncology has higher earnings, but lower revenue than Seagen. Insider and Institutional Ownership. 78.4% of Elevation Oncology shares...
About Elevation Oncology, Inc. Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.2M | 38 | 3% | N/A |
#2 | $5.9M | 38 | -25% | $2M |
#3 | N/A | 38 | 31% | N/A |
#4 | $4M | 38 | -19% | $26.2M |
#5 | $4M | 38 | -7% | $51.1M |